This review focuses on pathophysiology, clinical signs, and imaging of brain edema associated with intracranial tumors and its treatment. Brain edema in brain tumors is the result of leakage of plasma into the parenchyma through dysfunctional cerebral capillaries. The latter type of edema (ie, vasogenic edema) and the role of other types in brain tumors is discussed. Vascular endothelial growth factor-induced dysfunction of tight junction proteins probably plays an important role in the formation of edema. Corticosteroids are the mainstay of treatment of brain edema. When possible, corticosteroids should be used in a low dose (eg, 4 mg dexamethasone daily) to avoid serious side effects such as myopathy or diabetes. Higher doses of dexamethasone (16 mg/day or more), sometimes together with osmotherapy (mannitol, glycerol) or surgery, may be used in emergency situations. On tapering, one should be aware of the possible development of corticosteroid dependency or withdrawal effects. Novel therapies include vascular endothelial growth factor receptor inhibitors and corticotropin releasing factor, which should undergo further clinical testing before they can be recommended in practice.
Introduction
Brain edema is a prominent feature of brain cancer and often contributes to neurologic dysfunction and impaired quality of life. This review focuses on treatment of brain edema in brain tumors. Clinical features of patients with brain tumors are discussed, followed by pathologic and pathophysiologic aspects of brain edema, and methods for diagnosing its presence. The practice of corticosteroid administration, corticosteroid dependency, and withdrawal effects are discussed, together with a number of new agents that can influence the development of brain edema.
Clinical presentation
Papilledema, occipital headache worsening in the morning, nausea and vomiting, abnormal eye movements, and impaired consciousness are the classic signs of raised intracranial pressure. Headache can be a prominent feature of patients with brain edema and is probably caused by traction or pressure on pain-sensitive structures such as dural coverings and blood vessels. In one large series, 60% of patients with brain tumors reported headache. The pain seems dependent on size and location of the tumor (infra-vs supratentorial), presence of midline shift, a prior history of headaches, and the amount of edema surrounding the tumor [1, 2] . Headache in patients with cancer is an ominous sign: Intracranial metastases were found in more than 30% of cancer patients with headache as the presenting symptom. Headache duration of 10 weeks or less, emesis, and pain not of a tension type are significant clinical predictors for the presence of brain metastases in cancer patients [3] .
brain tumors present with focal neurologic deficits, and a similar percentage develops epilepsy [4, 5] .
Infratentorial lesions need special attention given the vulnerability of the brainstem. Under these conditions, a small amount of edema may result in severe symptoms of increased intracranial pressure such as impaired consciousness, and emergency treatment is often necessary.
Pathology and pathophysiology
During the last decade, pathophysiologic mechanisms of brain edema have been extensively studied. Brain edema can be defined as an expansion of brain volume resulting from an increase in water and sodium content. Two major types of edema can be characterized: intraand extracellular edema.
Intracellular edema
Increased intracellular water content results in cellular swelling. This type of edema is often the result of cytotoxic injury such as cerebral ischemia or trauma and is therefore called "cytotoxic edema." In this type of edema, the primary targets are the ATP-dependent sodium pumps: Energy depletion-induced dysfunction of these pumps results in increased intracellular sodium levels and, as a consequence, results in the accumulation of intracellular water. Cytotoxic edema is probably not an important component of brain tumor edema, although it may play a role in situations when (micro)circulation is impeded (eg, after brain herniation).
Extracellular edema
In the extracellular compartment, water can either be part of the cerebrospinal fluid or of the interstitial fluid. The production of interstitial fluid is probably driven by a pressure and osmotic gradient, is often called "bulk flow," and it may have a role in transporting nutrients and metabolites. An increase in extracellular water leads to brain edema. This type of edema is mostly located in the white matter. Its properties, consisting of axons running parallel to one other and surrounded by an extracellular space with a low cell density, would contribute to a concentration of the edema within the white matter and may also serve as a conduit for transporting fluid
The various types of extracellular edema are as follows.
Vasogenic edema is the most common type in brain tumors. As a result of increased brain capillary permeability and a pressure gradient from vascular to extracellular compartments, plasma leaks into the brain parenchyma and follows the pathways of bulk flow. This type of edema is described in more detail in the next section. Hydrocephalic edema is the result of the obstruction of cerebrospinal fluid flow. Edema is formed because of a hydrostatic pressure gradient between the ventricles and the brain parenchyma. Brain capillaries are not affected, and restitution of the normal cerebrospinal fluid flow will therefore lead to clearance of hydrocephalic edema. Osmotic edema is the result of an altered osmotic gradient between the plasma and the interstitial fluid. Severe osmotic edema can be seen after water intoxication, acute hyponatremia, or too rapid reduction of hyperosmolarity [7] . Stasis, induced by tumor in venous drainage areas (eg, compression of an adjacent cortical vein by the tumor), with stasis at the site of the compression, results in peritumoral edema [8] . An excretory-secretory mechanism in meningiomas in which tumor-produced substances appear in the peritumoral tissue was postulated in the 1980s. Based on electron microscopic studies, a close correlation was found between secretory activity and production of edema [9] . Hydrodynamic processes, in which fluids originate from the tumor itself, may contribute to the formation of edema. It was recently shown that contrast agent effusion from the extracellular space of meningiomas into the interstitium of the peritumoral tissue was detectable 3 to 6 hours after contrast administration [10•].
Morphologic and molecular alterations in the blood-brain barrier
The blood-brain barrier is a highly selective interface separating the brain from the blood. Its most important component is the capillary endothelial cell. In contrast to extracerebral capillaries, cerebral endothelial cells are nonfenestrated, lack intracellular clefts, contain low numbers of pinocytotic vesicles, have a high mitochondrial content, and are enclosed by astrocytic foot processes. These endothelial cells are connected by tight junctions, which have both a high electric impedance and a low permeability to polar solutes, and they contribute to the selective barrier in this way. Opening of tight junctions probably plays a key role in the formation of vasogenic brain edema. 
Vascular endothelial growth factor
VEGF was originally described as vascular permeability factor and it functions as a regulator of angiogenesis and vascular permeability [20] . VEGF binds to endothelial cells via interaction with the high-affinity tyrosine kinase receptors flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR2). These receptors are expressed predominantly on endothelial cells [21, 22] . VEGF has a very strong vascular permeability activity and is a thousand times more potent than histamine [23, 24] , and probably has direct effects on the endothelial tight junction (which is described later). Besides, VEGF induces edema formation via the synthesis and release of nitric oxide, an activator of cyclic GMP-dependent pathways [25] . VEGF may impair the function of occludin: VEGF phosphorylates occludin, with the opening of tight junctions as a consequence [18] . Others report that VEGF induces fenestration of the endothelium and enhances capillary permeability in this way [26] . The role and expression of VEGF in meningiomas and gliomas is discussed in the next section. VEGF-mediated vasogenic edema is presented in Figure 1 .
Alternative hypotheses on the formation and regulation of brain edema have been generated after the discovery of the aquaporin family. In the brain, aquaporin-4 is expressed in endothelial astrocytic foot processes. Aquaporin-4 is highly upregulated in high-grade gliomas [27, 28] . Whether this upregulation results in increased edema formation or in enhanced clearance of edema is still unclear.
Meningiomas
Meningiomas are extraaxial tumors comprising approximately 20% of all primary intracranial tumors. Meningiomas are separated from the brain by the arachnoid, the subarachnoid space, and the pia mater. In contrast to intraaxial tumors such as gliomas, the relation between VEGF expression and grade of malignancy is unclear. Therefore, the presence of edema does not automatically imply a high grade of malignancy. For example, secretory meningiomas are benign meningiomas (World Health Organization grade I) and display extensive edema surrounding the tumor [29-31]. These tumors do not display severe hypoxia, and other VEGF-regulating factors may be involved. Upregulation of VEGF is probably regulated by platelet-derived growth factor, epidermal growth factor, and estrogens in these tumors [32,33,34•].
Gliomas
VEGF expression in gliomas is largely dependent on the grade of malignancy. Low-grade gliomas express low levels of VEGF, and progression of low-grade gliomas into malignant gliomas is associated with an up to 50-fold increase in VEGF mRNA [35] . The expression of VEGF is largely restricted to the perinecrotic cells, suggesting that hypoxia regulates its expression in high-grade gliomas [36] . An exception to this rule seems to be pilocytic astrocytoma. This World Health Organization grade I tumor has a good prognosis and displays high levels 
Other mediators of edema
Apart from VEGF, other vasoactive substances released by the tumor itself or by the injured peritumoral tissue may contribute to the formation of brain edema. Arachidonic acid metabolites may be important in this respect: Elevated levels of leukotriene C4 (produced via the lipoxygenase pathway) are found in glioblastoma multiforme, as well as in the surrounding edematous tissue. More important, the concentration of leukotriene C4 correlates significantly with the amount of peritumoral edema [39, 40] . Another interesting aspect is the observation that the degree of peritumoral macrophage infiltration is associated with the amount of edema. This has prompted the suggestion that secretory products of macrophages would contribute to the formation of edema. The list of other potential vasogenic substances that may promote the development of brain edema is long, including serotonin, thromboxanes, and platelet-activating factor [41-43].
Imaging
Brain edema can be identified with CT and MRI. On CT and T1-weighted MRI, brain edema can be visualized as a hypodense or hypointense lesion. Brain edema and other structures with a high water (proton) content such as cerebrospinal fluid are hyperintense on T2-weighted MRI. Fluid-attenuated inversion-recovery MR images provide additive information, because brain edema is clearly visualized as a hyperintense lesion against an iso-or hypointense background. Fluidattenuated inversion recovery MRI has been compared with T2-weighted MRI in patients with meningiomas and is superior to T2-weighted images with respect to tumor delineation, contrast of tumor to cerebrospinal fluid, and contrast of tumor to brain parenchyma [44] .
Various methods can be used to display alterations in biochemistry in peritumoral brain edema. Changes in perfusion have recently been studied with dynamic perfusion-weighted MRI. Relative regional cerebral blood volume and flow were almost 50% lower in peritumoral brain edema than in the contralateral white matter in patients with meningiomas [45] . Others found significant reductions in blood flow, oxygen, and glucose in peritumoral edema using positron emission tomography [46] . Intraoperative studies have shown that peritumoral tissue oxygen levels increases up to threefold after decompression by opening the dura [47] .
Treatment
Specific therapies such as surgery, osmotherapy, and corticosteroids contribute to the treatment of brain edema and are described in the next sections. However, many patients may benefit from simple general or pharmacologic measures as well. Overhydration may lead to an increase in interstitial fluid accumulation, especially when the osmotic gradient is disturbed (eg, in hyponatremia). The observation that the diuretic furosemide has beneficial effects in combination with corticosteroids supports the importance of adequate hydration [48] . Furthermore, prevention of severe hypertension may be important: Hypertension leads to increased hydrostatic pressure and may lead to an increased generation rate of edema. However, blood pressure reduction should be done with care to prevent cerebral hypoperfusion and ischemia. Symptomatic epilepsy should be treated: Seizures create an increased metabolic need and blood flow, potentially leading to edema [49] .
Surgery
Surgery, for the purpose of edema treatment, should be considered only when life is in immediate danger. Especially, edema-induced obstructive hydrocephalus can be treated with shunting. Furthermore, surgery may be necessary in patients with extensive brain edema and impaired consciousness. However, surgery in patients with extensive brain edema may be associated with increased morbidity: It has been shown that intraoperative increases in intracranial pressure mostly occur in patients with large amounts of edema. Patients with extensive preoperative edema may also be at higher risk for postoperative edema and even brain herniation [50] [51] [52] . In practice, pharmacologic treatment with corticosteroids (which is described later) results in therapeutic effects within 24 to 48 hours and would help to avoid emergency surgery.
Osmotherapy
Osmotherapy with mannitol, glycerol, or hypertonic saline is often used in patients with severe brain edema after stroke or neurotrauma. A typical dose of, for example, mannitol is 1 g/kg (250 mL of a 20% solution in an average adult), resulting in a reduction in intracranial pressure of 30 to 60% for 2 to 4 hours [53] . Osmotherapy results in massive osmotic diuresis, so fluid and electrolyte balance should be monitored carefully.
Evidence from randomized studies for a role of osmotherapy in brain tumor edema is lacking (the same holds true for stroke and trauma). Osmotherapy may have negative effects in brain cancer as well. As a result of a disrupted blood-brain barrier, the osmotic agent may leak into the brain parenchyma, with further disturbance of the osmotic gradient as a result. An alternative to mannitol is glycerol. The "rebound phenomenon" after administration of an oral glycerol solution (40 mL 85% glycerol) may be less prominent, because this drug is metabolized intracellularly [54] . Interestingly, osmotherapy may even enhance disturbance of the bloodbrain barrier: Mannitol-induced shrinkage of cerebral capillaries results in the opening of endothelial tight junctions and is used (in experimental conditions) to allow passage of, for example, chemotherapeutics that normally cannot enter the brain parenchyma [55] . Regarding all the possible caveats of osmotherapy, we would not routinely recommend osmotherapy in patients with brain tumor edema.
Other methods such as hyperventilation, elevation of the head of the bed and fluid restriction may be applied, although true evidence is not available.
Corticosteroids
Corticosteroids have been in use since the 1960s, and although they are associated with substantial side effects, they play a decisive role in the management of brain edema associated with primary or secondary brain tumors [56] . The introduction of corticosteroid therapy in the early 1960s coincided with a remarkable decline in perioperative mortality rates and indicates the importance of these drugs [57] . Several mechanisms for corticosteroidinduced edema reduction have been proposed: inhibition of phospholipase A 2, an enzyme of the arachidonic acid cascade, stabilization of lysosomal membranes, and improvement of peritumoral microcirculation [58] .
Mechanisms of action
Corticosteroid treatment results in a decreased edema formation rate without a noticeable effect on absorption. Recent studies have shown that corticosteroids reduce the expression of the edema-producing factor VEGF [59, 60] . The edema-reducing effect of corticosteroids is rapid: Reductions in capillary permeability were observed already 1 hour after a single dose of a corticosteroid [61] . Apart from an edema-reducing effect, a reduction in tumor size of 15% after corticosteroid treatment has been observed, although this effect could not be confirmed by others [62, 63] .
Dexamethasone is the most commonly used corticosteroid. It is approximately six times as potent as prednisone (20 mg dexamethasone is equivalent to 130 mg prednisone) and reaches full effect within 24 to 72 hours. Dosages of dexamethasone vary between 4 to 100 mg/day. Dexamethasone has lower mineralocorticoid (saltretaining) effects than other corticosteroids. The latter effect may lead to increased risk of hyponatremia, which enhances the generation of edema. Therefore, some authors prefer prednisone instead of dexamethasone [54] . A comparison of dexamethasone with other corticosteroids is presented in Table 1 .
Randomized trial
One randomized study has addressed the therapeutic effects and side effects of corticosteroids. Ninety-six patients with brain metastases were randomized between 4, 8, and 16 mg/day dexamethasone. Administration of 4 mg/day or 16 mg/day dexamethasone resulted in the same improvement in neurologic function. However, the increase in side effects was dose dependent. Treatment with 16 mg/day dexamethasone resulted in a an approximate 25% increase in the percentage of patients with proximal muscle weakness 4 weeks after the start of steroid treatment. Muscle weakness did not increase after 4 mg/day [64•]. The percentage of cushingoid faces increased significantly (32% vs 65%, 4 mg/day vs 16 mg/day; P = 0.03). These data indicate that many patients can be treated with 4 mg dexamethasone/day, resulting in significantly less side effects. In patients with impaired consciousness or signs of increased intracranial pressure, we would recommend 10 mg intravenously, followed by 4 × 4 mg/day orally.
Side effects
Apart from steroid myopathy, which may be the result of catabolic effects of corticosteroids, and cushingoid faces (resulting from the characteristic redistribution of fat from peripheral to central parts of the body), other serious side effects are prominent after (high-dose) steroid treatment [65] .
Almost 50% of patients treated with corticosteroids over a longer period develop a disturbed glucose metabolism, and in nearly half of these patients, disturbances persist despite reduction or even withdrawal of the drug [66] .
Meta-analyses of the magnitude of the risk corticosteroid-induced peptic ulcers provide conflicting results [67, 68] . Treatment with H2 blockers or proton pump inhibitors is recommended in patients receiving drugs with potential gastrointestinal side effects, such as nonsteroidal antiinflammatory drugs, anticoagulants, and high doses of dexamethasone. Also, in the elderly, perioperative conditions or in patients with a prior history of peptic ulcer may benefit from peptic ulcer prophylactics [69•]. Psychiatric complications in patients receiving corticosteroids seem to be dose dependent as well. A total of 676 patients free of psychiatric disease were investigated before corticosteroid treatment in the early 1970s. Severe psychiatric illness (ie, psychosis, mania, or depression) was uncommon (1.3%) after receiving less than 40 mg/day prednisone (equivalent to 3 mg/day dexamethasone), but increased to 18.5% at doses more than 80 mg/day prednisone (equivalent to 12 mg/day dexamethasone; as reviewed by Brown and Chandler [70] ).
Patients with brain tumors receiving steroids are also at risk for Pneumocystis carinii pneumonia. In one study of brain tumors, the reported incidence was almost 2% [71] . Prophylactic treatment with trimethoprim-sulfamethoxazole may prevent this potentially life-threatening pneumonia and is mainly applied to patients who have additional reasons for being immune compromised.
Withdrawal of corticosteroids
After successful treatment (eg, gross tumor resection), corticosteroids can be tapered. Corticosteroids should be tapered within 2 to 3 weeks. Decreasing the dose by 50% every 4 days is a reasonable approach in patients with a good clinical condition. However, patients with poorly controlled tumors or extensive brain edema may deteriorate after rapid tapering. Corticosteroids should be tapered by 25% every 8 days in the latter group. Eventually, chronic treatment with a low dose of corticosteroids (eg, 1 to 2 mg/day) may be needed to have an acceptable quality of life. However, the risk of long-term side effects is increased in these patients.
Withdrawal of corticosteroids is associated with morbidity as well. The so-called "steroid withdrawal syndrome" was described in the 1960s and is characterized by arthralgias, myalgias, and more general symptoms such as headache, lethargy, and sometimes low-grade fever [72] . Especially, leg and joint pain can be severe and may result in an inability to walk. The steroid withdrawal syndrome usually follows rapid tapering of corticosteroids (particularly after prolonged periods of high-dose use), although it may occur on slow tapering (2 mg dexamethasone/week) [73] .
Another side effect of corticosteroid withdrawal is adrenal insufficiency. Administration of corticosteroids induces a negative feedback on the hypothalamicpituitary-adrenal axis. Tapering that occurs too fast may lead to secondary adrenal insufficiency with weakness, pigmentation of skin, and weight loss as the most prominent symptoms. Acute adrenal insufficiency is a feared but probably rare complication and may lead to hypotension that is refractory to fluids and requires vasopressors and intensive care unit admission.
Novel treatments
Corticotropin-releasing factor (CRF) is an endogenous peptide responsible for the secretion and synthesis of corticosteroids, and has been studied in animal models and in patients.
Rats with intracerebral gliomas were treated systemically with human CRF or dexamethasone. Both agents effectively decreased blood-brain barrier permeability measured with MRI. Increased levels of adrenal corticosteroids were not observed, and it has been concluded that human CRF has a direct action on tumor microvasculature, resulting in restoration of blood-brain barrier integrity [74] .
Intravenously administered human CRF resulted in recovery of neurologic function in 10 of 17 patients with brain metastases. Improvement in symptoms did not correlate with changes in cortisol levels. Only a small change in brain edema was detected with MRI after CRF treatment. Dose-limiting toxicity (hypotension) was observed at a dose of 4 µg/kg/hour. Flushing and hot flashes were also observed. Lower doses did not result in severe toxicity [75] . Although long-term side effects have not been investigated, the data indicate that further studies are necessary.
Selectively inhibiting VEGF may be effective, and data from experimental studies are promising: SU5416, a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR, was administrated systemically in rats with intracerebral gliosarcoma. SU5416 prolonged survival without any significant systemic adverse effect. Histologic analysis of the treated tumors showed an increase in necrosis and reduced vascularity after treatment with SU5416 [76] . SU5416 is currently being tested in various phase II studies and has shown biologic activity in patients with hematologic malignancies [77, 78] .
The cyclooxygenase-2 inhibitor SC-236 has been investigated recently. Rats with intracerebral gliosarcomas received SC-236, dexamethasone, or no treatment. Median survival increased almost 50% after SC-236 or dexamethasone treatment [79] . In another study, rats with intracerebral gliosarcomas were treated with rofecoxib, another selective cyclooxygenase-2 inhibitor. Rofecoxib was as effective as dexamethasone in decreasing the diffusion of contrast material into the brain parenchyma, suggesting a reduction in blood-tumor barrier permeability. The data from the aforementioned studies indicate that selective cyclooxygenase-2 inhibitors appear to be as effective as dexamethasone in preventing brain edema and that survival is enhanced in these animal models. In the past, other nonsteroidal antiinflammatory drugs have shown variable results in animal models [80] . In a small series, the classic cyclooxygenase-2 inhibitor ibuprofen improved the Karnofsky performance score in 40% of patients [81] . Novel cyclooxygenase-2 inhibitors need further testing in humans with tumor-induced brain edema.
Conclusion
Corticosteroids are the mainstay of treatment for brain edema. Side effects are acceptable when using low doses of steroids (eg, dexamethasone 2 × 2 mg/day orally). In acute situations, a bolus of 10 mg dexamethasone intravenously may be necessary, followed by 16 mg dexamethasone in divided daily doses. Corticosteroids should be tapered or maintained at the lowest effective dose when possible. General therapeutic measures such as regulation of fluid, electrolyte balance, and serum glucose, and treatment of seizures and severe hypertension may help to prevent further clinical deterioration. Proton pump inhibitors or H2 blockers and PCP prophylactics should be used on indication. Surgery as a means of edema treatment only and osmotherapy are associated with potentially serious side effects and should be used in emergency situations only. Experimental treatment with CRF, VEGF, and cyclooxygenase inhibitors seems promising, but should undergo further clinical testing before it can be recommended for use in routine practice.
References and recommended reading
Papers of particular interest, published within the annual period of review, are highlighted as:
• Of special interest 
